TACE is most commonly used in the treatment of primary liver cancer (HCC). It is often considered for patients who:
- Are ineligible for surgical resection or liver transplantation. - Have tumors that are too large or too numerous to be treated with ablation. - Have intermediate-stage HCC according to the Barcelona Clinic Liver Cancer (BCLC) staging system.
TACE may also be used for treating metastatic liver cancer and, in some cases, for cancers of other organs where traditional systemic chemotherapy has not been effective.
